Navigation Links
Mayo study shows stroke incidence related to angioplasty remains steady over past 15 years
Date:11/16/2009

ORLANDO, Fla. - Results of a Mayo Clinic study show the incidence of stroke or mini-stroke related to a coronary angioplasty (http://www.mayoclinic.org/heart-catheterization/types.html) remained steady over a 15-year period. Researchers say this is good news because physicians now are performing the artery-opening procedure on older patients who are sicker and need more complicated treatment.

The results will be presented today at the American Heart Association's Scientific Sessions (http://www.americanheart.org/presenter.jhtml?identifier=1200000) 2009 in Orlando, Fla.

Angioplasty, a procedure used to open clogged arteries, can improve chest pain or shortness of breath, or open an artery quickly to reduce damage to the heart during an attack. During angioplasty, also known as percutaneous coronary intervention (PCI), a tiny balloon is temporarily inserted and inflated to unclog and widen the artery. In some cases, a small metal coil called a stent is placed in the artery to keep it propped open.

In a retrospective study of 17,249 patients who had 21,502 angioplasty procedures between 1994 and 2008 at Mayo Clinic in Rochester, Minn., the researchers identified patients who suffered an angioplasty-related cerebrovascular accident (CVA), defined as a stroke, or a transient ischemic attack (TIA or mini-stroke), and compared outcomes with the remainder of the study population, according to senior author Rajiv Gulati, M.D., Ph.D. (http://www.mayoclinic.org/bio/13906658.html), a Mayo Clinic cardiologist. Eighty-four patients, or three or four in 1,000 patients, had a stroke or a TIA, and 23 percent of those were mini-strokes, Dr. Gulati says.

The low number of patients who had a stroke was somewhat surprising, he says. "Given that we are now dealing with older and sicker patients, with more extensive blockages requiring more complex treatment, we found the current incidence of stroke related to this procedure to still be very low indeed," he says.

The research showed that patients with CVA were more likely to be older (average age was 74 years old versus 66 years old), female (52 percent versus 29 percent), have moderate-to-severe renal disease (8 percent versus 3.7 percent) and have a history of stroke unrelated to prior angioplasty (31 percent versus 11 percent).

This study helps physicians recognize patients who are at higher risk of stroke or TIA, Dr. Gulati says. And if a patient has a stroke or TIA related to angioplasty treatment, technologies to use clot-busting drugs or remove the clot are more readily available today. "We now have newer technologies that can deal with stroke should the worst happen," he says. "And recognizing patients at higher risk puts us in a good position to help."

The research also showed that other factors were predictors of CVA, such as the number of diseased coronary arteries, presence of intracoronary thrombus, an increased number of vessels treated and the need for emergency angioplasty.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Shire announces publication of open-label study on coadministration of INTUNIV with stimulants
2. Study Touts Success With Female Viagra Drug
3. Study Raises New Questions About Cholesterol Drug Zetia
4. First ever large-scale study of ketamine users published
5. Swan Study Authors Note Results Not Straightforward
6. Pilot study relates phthalate exposure to less-masculine play by boys
7. New Study Raises New Questions About Cholesterol Drug Zetia
8. XOLAIR Safety Study Continues to 2012 Despite Increased Rate of Occurrence of Heart Problems, Onder Law Firm Offers Free XOLAIR Case Review
9. Independent Clinical Study Finds Vemma is Highly Bioavailable Showing Increase in Vitamins and Antioxidants in the Blood*
10. Study Links Yo-Yo Dieting to Addiction
11. Underground mine ventilation subject of study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... will lecture to primary eye care practitioners on the latest breakthroughs in the ... 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New ... the region, is launching a charity drive to raise awareness of heart disease and ... killer in America, and is responsible for 1 in every 4 deaths at the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... Tyler, TX (PRWEB) , ... January 17, 2017 ... ... serving Texas families from two offices in Tyler, has announced the latest beneficiary ... Red Ribbon Wish Network, a nonprofit organization dedicated to fulfilling the dreams of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene ... vice president, research and pharmaceutical development at Tocagen, will present at ... held Jan. 17-20 in Miami . ... ... manufacturing for replicating viruses - what to do when and why ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
(Date:1/17/2017)... , Jan. 17, 2017 Immune Pharmaceuticals (NASDAQ: ... company, announced today that it will hold a Satellite Symposium ... Acute Leukemias (ISAL) XVI in Munich, Germany ... "Reinforcing the Efficacy of Immunotherapy for the maintenance of ... on Monday February 20 th , 2017 from 12:45 – ...
Breaking Medicine Technology: